Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
Open Access
- 15 March 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 33 (9), 1049-1057
- https://doi.org/10.1093/eurheartj/ehr437
Abstract
Glycaemic control is an inadequate surrogate marker of cardiovascular event reduction in patients with type 2 diabetes. Clinical trials to date have been unsuccessful in identifying a therapeutic approach that addresses the underlying problem in diabetes (glycaemic control) and reduces cardiovascular risk. The potential for some agents to increase the risk of cardiovascular events has led to substantial changes in regulatory requirements for new anti-diabetic therapies. These requirements, while key to ensuring the cardiovascular safety of new agents, fail to emphasize the need to show clinical benefits, such as less visual impairment, less need for dialysis, or fewer cardiovascular events and deaths. Changes in test results such as glycaemic control, serum creatinine, micro-albuminuria, or retinopathy are inadequate surrogates. Regulators should consider the potential advantages of offering extended patent protection in order to encourage companies to conduct long-term trials in diabetes and many other chronic medical conditions. Cooperative efforts among physicians, clinical trialists, regulators, and sponsors are needed to address unresolved issues including re-defining therapeutic targets that are meaningful to patients with diabetes, determining the appropriate length of follow-up for future trials, and considering the ethical and operational challenges of non-inferiority designs.This publication has 57 references indexed in Scilit:
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsThe Lancet, 2011
- Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding?Diabetes Care, 2010
- Effects of Medical Therapies on Retinopathy Progression in Type 2 DiabetesThe New England Journal of Medicine, 2010
- Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD TrialDiabetes Care, 2010
- Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialEuropean Heart Journal, 2010
- The Pathologic Continuum of Diabetic Vascular DiseaseJournal of the American College of Cardiology, 2009
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008